Goury Antoine, Djerada Zoubir, Hernandez Glenn, Kattan Eduardo, Griffon Romain, Ospina-Tascon Gustavo, Bakker Jan, Teboul Jean-Louis, Hamzaoui Olfa
Unité de Médecine Intensive et Réanimation Polyvalente, CHU Reims, Reims, F-51100, France.
Université de Reims Champagne-Ardenne, Unité HERVI "Hémostase et Remodelage Vasculaire Post- Ischémie" - EA 3801, Reims, F-51100, France.
Ann Intensive Care. 2025 Mar 26;15(1):43. doi: 10.1186/s13613-025-01454-y.
Septic shock is commonly associated with reduction in vasomotor tone, mainly due to vascular hyporesponsiveness to norepinephrine (NE). Although the diastolic arterial pressure (DAP)/heart rate (HR) ratio reflects vasomotor tone, it cannot be a reliable index of vascular responsiveness to NE (VNERi). We hypothesized that adjusting DAP/HR for the NE dose could yield a VNERi value (VNERi = DAP/(NE dose x HR)), knowledge of which can help guiding therapeutic strategies in cases of persistent hypotension despite NE (e.g., increasing NE doses vs. introducing additional vasopressors). For our hypothesis be valid, at least VNERi should demonstrate a stronger association with patient outcome than DAP, DAP/HR or mean arterial pressure (MAP)/NE dose, a global marker of NE responsiveness.
We conducted a post-hoc analysis of the ANDROMEDA-SHOCK database. Hemodynamic variables and initial NE doses were recorded at the randomization time-point, within 4 h of septic shock diagnosis. NE doses were expressed in µg/kg/min (using the bitartrate NE formulation). A multivariate model was employed to compare the associations between these variables and key clinical outcomes, including in-hospital mortality, numbers of vasopressor-free days and of renal replacement therapy (RRT)-free days up to day 28.
The ANDROMEDA-SHOCK database included 424 patients with septic shock receiving NE. The median DAP was 52 mmHg [IQR: 45-50] and the median NE dose at inclusion was 0.2 µg/kg/min [IQR: 01-0.4]. In-hospital mortality was 43%. VNERi demonstrated the strongest association with in-hospital mortality compared to DAP, DAP/HR, and MAP/NE dose, emerging as the most significant covariate in the multivariate model. Similar findings were found for the associations with numbers of vasopressor-free days and RRT-free days up to day 28. The model revealed an inverted J-shaped relationship between in-hospital mortality and VNERi, with a nadir point at 6.7, below which mortality increased.
In patients receiving NE during early septic shock, VNERi demonstrated the strongest association with outcome compared to DAP, DAP/HR, and MAP/NE dose. Due to its physiological basis and robust association with outcomes, VNERi may serve as a valuable bedside marker of the vascular responsiveness to NE. This index could potentially be integrated into decision-making of early septic shock.
脓毒性休克通常与血管运动张力降低有关,主要是由于血管对去甲肾上腺素(NE)反应性降低。虽然舒张压(DAP)/心率(HR)比值反映血管运动张力,但它不能作为血管对NE反应性(VNERi)的可靠指标。我们假设,用NE剂量校正DAP/HR可得出VNERi值(VNERi = DAP/(NE剂量×HR)),了解该值有助于指导尽管使用了NE但仍持续低血压的病例的治疗策略(例如,增加NE剂量与加用其他血管加压药)。为使我们的假设成立,至少VNERi应比DAP、DAP/HR或平均动脉压(MAP)/NE剂量(NE反应性的整体指标)与患者预后有更强的相关性。
我们对ANDROMEDA-SHOCK数据库进行了事后分析。在脓毒性休克诊断后4小时内的随机化时间点记录血流动力学变量和初始NE剂量。NE剂量以μg/kg/分钟表示(使用重酒石酸NE制剂)。采用多变量模型比较这些变量与关键临床结局之间的相关性,包括住院死亡率、无血管加压药天数和至第28天的无肾脏替代治疗(RRT)天数。
ANDROMEDA-SHOCK数据库纳入了424例接受NE治疗的脓毒性休克患者。DAP中位数为52 mmHg [四分位间距(IQR):45 - 50],纳入时NE剂量中位数为0.2 μg/kg/分钟 [IQR:0.1 - 0.4]。住院死亡率为43%。与DAP、DAP/HR和MAP/NE剂量相比,VNERi与住院死亡率的相关性最强,成为多变量模型中最显著的协变量。在与至第28天的无血管加压药天数和无RRT天数的相关性方面也有类似发现。该模型显示住院死亡率与VNERi之间呈倒J形关系,最低点为6.7,低于该值死亡率增加。
在脓毒性休克早期接受NE治疗的患者中,与DAP、DAP/HR和MAP/NE剂量相比,VNERi与预后的相关性最强。由于其生理基础以及与预后的密切相关性,VNERi可能作为血管对NE反应性的有价值的床边指标。该指标可能会被纳入早期脓毒性休克的决策制定中。